Antenatal maternal administration of phenobarbital for the prevention of exchange transfusion in neonates with hemolytic disease of the fetus and newborn


      Hemolytic disease of the fetus and newborn infant (HDFN) can be associated with bilirubin encephalopathy, which is usually averted through neonatal exchange transfusions (EXT). However, EXT can be associated with significant procedure-related morbidity. We hypothesized that maternal oral administration of phenobarbital (PB) to women with HDFN would reduce the rate of EXT.

      Study design

      Cases of HDFN from January 1985 to June 2003 were reviewed. All patients who underwent serial intrauterine transfusions (IUTs) for red cell alloimmunization were included. Patients were offered oral phenobarbital (30 mg 3 times a day) after their last IUT in an effort to enhance fetal hepatic maturity. Variables studied included gestational age and hemoglobin multiples of the median at first transfusion and delivery, peak neonatal bilirubin, need for exchange transfusion, and maternal PB administration. Multivariate regression analysis was applied to determine relative risks and 95% CIs.


      Seventy-one patients met study criteria; 29% of the neonates underwent EXT. The use of antenatal PB was associated with a decreased incidence of EXT, 9% versus 52% (P < .01). After controlling for confounding variables, the relative risk for EXT after antenatal PB administration was 0.23 (95% CI: 0.06-0.76).


      Maternal administration of PB reduces the need for neonatal EXTs in HDFN.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Yamamoto K.
        • Sato H.
        • Fujiyama Y.
        • Doida Y.
        • Bamba T.
        Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II.
        Biochim Biophys Acta. 1998; 1406: 267-273
        • Brown A.K.
        • Zuelzer W.W.
        Studies on the neonatal development of the glucuronide conjugating system.
        J Clin Invest. 1958; 37: 332-340
        • Gartner L.M.
        • Arias I.M.
        The transfer of bilirubin from blood to bile in the neonatal guinea pig.
        Pediatr Res. 1969; 3: 171-180
        • Catz C.
        • Yaffe S.J.
        Barbiturate enhancement of bilirubin conjugation and excretion in young and adult animals.
        Pediatr Res. 1968; 2: 361-370
        • Trolle D.
        A possible drop in first-week-mortality rate for low-birth-weight infants after phenobarbitone treatment.
        Lancet. 1968; 2: 1123-1124
        • Sugatani J.
        • Kojima H.
        • Ueda A.
        • Kakizaki S.
        • Yoshinari K.
        • Gong Q.H.
        • et al.
        The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR.
        Hepatology. 2001; 33: 1232-1238
        • Keenan W.J.
        • Novak K.K.
        • Sutherland J.M.
        • Bryla D.A.
        • Fetterly K.L.
        Morbidity and mortality associated with exchange transfusion.
        Pediatrics. 1985; 75: 417-421
        • Liley A.W.
        Liquor amnil analysis in the management of the pregnancy complicated by resus sensitization.
        Am J Obstet Gynecol. 1961; 82: 1359-1370
        • Mari G.
        • Deter R.L.
        • Carpenter R.L.
        • Rahman F.
        • Zimmerman R.
        • Moise Jr., K.J.
        • et al.
        Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses.
        N Engl J Med. 2000; 342: 9-14
      1. Practice parameter: management of hyperbilirubinemia in the healthy term newborn. American Academy of Pediatrics. Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia.
        Pediatrics. 1994; 94: 558-565
        • Maisels M.J.
        in: Glenn Brown Avery M.A.F. Mary Glenn MacDonald Neonatology: pathophysiology and management of the newborn. JB Lippincott, Philadelphia1999: 765-819
        • Maisels M.J.
        • Watchko J.F.
        Treatment of jaundice in low birthweight infants.
        Arch Dis Child Fetal Neonatal Ed. 2003; 88: F459-F463
        • Watchko J.F.
        • Oski F.A.
        Kernicterus in preterm newborns: past, present, and future.
        Pediatrics. 1992; 90: 707-715
        • Halpin T.F.
        • Jones A.R.
        • Bishop H.L.
        • Lerner S.
        Prophylaxis of neonatal hyperbilirubinemia with phenobarbital.
        Obstet Gynecol. 1972; 40: 85-90
        • Melchior J.C.
        • Svensmark O.
        • Trolle D.
        Placental transfer of phenobarbitone in epileptic women, and elimination in newborns.
        Lancet. 1967; 2: 860-861
        • Arpino C.
        • Brescianini S.
        • Robert E.
        • Castilla E.E.
        • Cocchi G.
        • Cornel M.C.
        • et al.
        Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE).
        Epilepsia. 2000; 41: 1436-1443
        • De Carolis M.P.
        • Romagnoli C.
        • Frezza S.
        • D'Urzo E.
        • Muzii U.
        • Mezza A.
        • et al.
        Placental transfer of phenobarbital: what is new?.
        Dev Pharmacol Ther. 1992; 19: 19-26
        • Thorp J.A.
        • O'Connor M.
        • Jones A.M.
        • Hoffman E.L.
        • Belden B.
        Does perinatal phenobarbital exposure affect developmental outcome at age 2?.
        Am J Perinatol. 1999; 16: 51-60
        • Thorp J.A.
        • O'Connor M.
        • Belden B.
        • Etzenhouser J.
        • Hoffman E.L.
        • Jones P.G.
        Effects of phenobarbital and multiple-dose corticosteroids on developmental outcome at age 7 years.
        Obstet Gynecol. 2003; 101: 363-373
        • Rayburn W.
        • Donn S.
        • Piehl E.
        • Compton A.
        Antenatal phenobarbital and bilirubin metabolism in the very low birth weight infant.
        Am J Obstet Gynecol. 1988; 159: 1491-1493
        • Shankaran S.
        • Cepeda E.E.
        • Ilagan N.
        • Mariona F.
        • Hassan M.
        • Bhatia R.
        • et al.
        Antenatal phenobarbital for the prevention of neonatal intracerebral hemorrhage.
        Am J Obstet Gynecol. 1986; 154: 53-57